Overview

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Status:
RECRUITING

Trial end date:
2032-09-01

Target enrollment:

Participant gender:

Summary

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489

Phase:

PHASE2

Details

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborator:

Bristol-Myers Squibb

Treatments:

durvalumab